Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 51–60, page 6 of 20. Filter these by subject, year and score in the research library →

1. Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriersResearch summary

   Research summaries · alzhub.org/study/real-world-lecanemab-adoption-in-japan-1-year-after-launch-insights-41114448

   Lecanemab was approved for early Alzheimer's disease in Japan, with ≈ 6000 patients treated in the first year post approval. This study explores real-world practices, challenges, and potential solutions. We conducted an …

2. [Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 ‍mg, 500 ‍mg for Intravenous Infusion), a novel treatment for Alzheimer's disease]Research summary

   Research summaries · alzhub.org/study/mechanism-of-action-and-clinical-trial-results-of-lecanemab-leqembi-38692883

   Lecanemab is a humanized monoclonal antibody directed against human soluble amyloid-β aggregates. It was developed for the treatment of early Alzheimer's disease (mild cognitive impairment or mild dementia stage of Alzheimer's …

3. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemabResearch summary

   Research summaries · alzhub.org/study/a-real-world-disproportionality-analysis-of-fda-adverse-event-40242445

   … (AEs) associated with lecanemab have been limited. Results A total of 811 AEs reports related to lecanemab used in AD patients and 506 AEs in Non-AD patients were included. Among these, ARIA-E, ARIA-H, brain oedema and status …

4. Characterization of the Anti-Alzheimer Drug Lecanemab by Mass SpectrometryResearch summary

   Research summaries · alzhub.org/study/characterization-of-the-anti-alzheimer-drug-lecanemab-by-mass-42368154

   -glycans found at the N304 site of lecanemab of the heavy chain. Further analysis by MSFragger identified other modifications and additional glycosites. These results provide data as resource for the identification of critical …

5. Disparities in Early Lecanemab Uptake Among US Medicare BeneficiariesResearch summary

   Research summaries · alzhub.org/study/disparities-in-early-lecanemab-uptake-among-us-medicare-beneficiaries-40372759

   … impairment received lecanemab and whether some groups were less likely to get it. It reports on uptake patterns only, not on whether the drug helped those patients. This cross-sectional study examines lecanemeb update among …

6. Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and LecanemabResearch summary

   Research summaries · alzhub.org/study/monoclonal-antibody-treatments-for-alzheimer-s-disease-aducanumab-and-39726673

   … gantenerumab, solanezumab, and lecanemab. These treatment approaches are grounded in the hypothesis that a systemic failure in clearing Aβ contributes to the initiation and progression of AD. Recently, aducanumab and lecanemab …

7. Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and ChallengesResearch summary

   Research summaries · alzhub.org/study/review-of-donanemab-and-lecanemab-in-mild-dementia-stage-of-alzheimer-41966037

   … antibodies (mAbs), notably lecanemab and donanemab, which target Aβ pathology in early-stage AD. This review explores the clinical efficacy, safety profile, and limitations of lecanemab and donanemab, emphasizing key findings …

8. Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/changes-of-a-cerebral-cavernous-malformation-associated-with-40584633

   … treatment with intravenous lecanemab. Baseline MRI revealed 3 lobar microhemorrhages and an asymptomatic left orbitofrontal cavernous malformation. This cavernous malformation exhibited gross radiologic stability at surveillance …

9. Clinical Practice Outcomes With Lecanemab for Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/clinical-practice-outcomes-with-lecanemab-for-alzheimer-disease-42746606

   … findings inform real-world lecanemab safety and efficacy. Dual ARIA-E peaks at ~10 and ~25 weeks underscore the need for ongoing MRI monitoring. Although several markers showed modest negative predictive value, none reliably …

10. Lecanemab for mild Alzheimer disease - is there a way forward?Research summary

    Research summaries · alzhub.org/study/lecanemab-for-mild-alzheimer-disease-is-there-a-way-forward-40078953

    … and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab, followed by its …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-14. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.